Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its ...

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.

Novavax (NVAX) announced that the U.S. FDA has removed the clinical hold on Novavax’s Investigational New Drug application for its ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...